ADC Therapeutics SA Earnings Per Share (Basic)
ADC Therapeutics SA (ADCT) reported Earnings Per Share (Basic) of -$0.11 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- ADC Therapeutics SA earnings per share, basic for the quarter ending 2026-06-30 was -$0.11.
- ADC Therapeutics SA earnings per share, basic for the quarter ending 2026-03-31 was -$0.21.
- ADC Therapeutics SA earnings per share, basic for the quarter ending 2025-12-31 was -$0.04.
- ADC Therapeutics SA earnings per share, basic for the quarter ending 2025-09-30 was -$0.30.
- ADC Therapeutics SA earnings per share, basic for fiscal 2025 was -$1.12.
- ADC Therapeutics SA earnings per share, basic for fiscal 2024 was -$1.62.
- ADC Therapeutics SA earnings per share, basic for fiscal 2023 was -$2.94.
- ADC Therapeutics SA earnings per share, basic for fiscal 2022 was -$2.01.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.11 10-Q · filed 2026-08-13 | -$0.32 10-Q · filed 2026-08-13 | -$0.36 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.65 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2026-03-31 | -$0.21 10-Q · filed 2026-05-04 | -$0.26 derived: net income ÷ weighted average shares · filed 2026-05-04 | -$0.55 derived: net income ÷ weighted average shares · filed 2026-05-04 | -$0.99 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-12-31 | -$0.04 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$0.33 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$0.78 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.12 10-K · filed 2026-03-10 |
| 2025-09-30 | -$0.30 10-Q · filed 2025-11-10 | -$0.78 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.14 10-Q · filed 2025-11-10 | -$1.44 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-06-30 | -$0.50 10-Q · filed 2026-08-13 | -$0.86 10-Q · filed 2026-08-13 | -$1.16 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.58 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-03-31 | -$0.36 10-Q · filed 2026-05-04 | -$0.65 derived: net income ÷ weighted average shares · filed 2026-05-04 | -$1.07 derived: net income ÷ weighted average shares · filed 2026-05-04 | -$1.45 derived: net income ÷ weighted average shares · filed 2026-05-04 |
| 2024-12-31 | -$0.29 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$0.71 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$1.09 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$1.62 10-K · filed 2026-03-10 |
| 2024-09-30 | -$0.42 10-Q · filed 2025-11-10 | -$0.80 derived: net income ÷ weighted average shares · filed 2025-11-10 | -$1.35 10-Q · filed 2025-11-10 | -$2.32 derived: net income ÷ weighted average shares · filed 2026-04-20 |
| 2024-06-30 | -$0.38 10-Q · filed 2025-08-12 | -$0.93 10-Q · filed 2025-08-12 | -$1.94 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$2.51 derived: net income ÷ weighted average shares · filed 2026-04-20 |
| 2024-03-31 | -$0.56 10-Q · filed 2025-05-14 | -$1.60 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$2.17 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$2.77 derived: net income ÷ weighted average shares · filed 2026-04-20 |
| 2023-12-31 | -$1.03 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$1.60 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$2.20 derived: net income ÷ weighted average shares · filed 2026-04-20 | -$2.94 10-K · filed 2025-03-27 |
| 2023-09-30 | -$0.57 10-Q · filed 2024-11-07 | -$1.17 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$1.90 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$0.60 10-Q · filed 2024-08-06 | -$1.33 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | -$0.73 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | -$2.01 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |